New York, October 03, 2014 -- Moody's Investors Service commented that the termination of the merger agreement between Salix Pharmaceuticals, Ltd. ("Salix") and Cosmo Technologies Limited ("Cosmo Tech") eliminates a credit positive benefit for Salix. There is no impact on Salix's ratings including the B1 Corporate Family Rating, or the stable rating outlook.

Vollständigen Artikel bei Moodys lesen